Evotec SE announced today that the Company’s Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take over from Enno Spillner whose contract will expire at the end of March and who will pursue new opportunities. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-laetitia-rouxel-to-succeed-enno-spillner-as-chief-financial-officer-6249
Evotec announces agreement with Janssen to develop immune-based therapies
Evotec SE announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-agreement-with-janssen-to-develop-immune-based-therapies-6247
Evotec-partner Sernova provides update on development of iPSC-derived cell therapy for diabetes
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE. This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch™ device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-sernova-provides-update-on-development-of-ipsc-derived-cell-therapy-for-diabetes-6245
Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb
Evotec SE announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb. The collaboration expands the portfolio by two additional drug discovery projects and has designated a target-based programme for further development, triggering payments in total of US$ 26 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-further-progress-in-neuroscience-collaboration-with-bristol-myers-squibb-6243
EVT801 pre-clinical data published in peer-reviewed cancer research journal
Evotec partner Kazia Therapeutics Limited, an oncology-focused drug development company, announced the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evt801-pre-clinical-data-published-in-peer-reviewed-cancer-research-journal-6241
Evotec substiantially reduces carbon emissions by joining renewable energy heating network
Evotec SE announced today that the Company will substantially reduce its carbon emissions by joining the renewable energy heating network Toulouse Energie Durable (“TED”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-substiantially-reduces-carbon-emissions-by-joining-renewable-energy-heating-network-6239
Evotec's partner Exscientia receives first CTA approval for Phase I/II trial of EXS-21546
Evotec’s partner Exscientia plc today announced clinical trial application (“CTA”) approval of a Phase I/II trial of EXS-21546, an A2a receptor antagonist, co-invented and developed through a collaboration between Exscientia and Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-exscientia-receives-first-cta-approval-for-phase-iii-trial-of-exs-21546-6237
Evotec SE reports results for the first nine months 2022 and provides corporate update
Evotec SE today announced the financial results and corporate updates for the first nine months 2022. Group revenues increased by 19% (13% excluding fx-effects) to € 510.8 m (9M 2021: € 431.0 m), despite significantly lower milestones, upfronts and license payments compared to a very strong comparable basis in 2021 (9M 2022: € 8.1 m vs. € 36.5 m in 9M 2021); base business at € 502.7 m continued to show very strong growth of 27% (9M 2021: € 394.5 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-nine-months-2022-and-provides-corporate-update-6235
Evotec completes acquisition of Central Glass Germany
Evotec SE announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-central-glass-germany-6230
Evotec SE to announce results for the first nine months 2022 on 09 November 2022
Evotec SE will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-the-first-nine-months-2022-on-09-november-2022-6232